Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma

被引:2
|
作者
Dolman, M. Emmy M. [1 ]
den Hartog, Ilona J. M. [1 ]
Molenaar, Jan J. [1 ]
Schellens, Jan H. M. [2 ,3 ]
Beijnen, Jos H. [2 ,3 ,4 ]
Sparidans, Rolf W. [2 ]
机构
[1] Univ Amsterdam, Amsterdam Med Ctr, Dept Oncogen, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Utrecht, Fac Sci, Dept Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, NL-3584 CG Utrecht, Netherlands
[3] Netherlands Canc Inst, Dept Clin Pharmacol, NL-1066 CX Amsterdam, Netherlands
[4] Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
关键词
Sepantronium bromide; Survivin suppressant; LC-MS/MS; Plasma; NEUROBLASTOMA;
D O I
10.1016/j.jpba.2014.01.011
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A quantitative bioanalytical liquid chromatography-tandem mass spectrometric (LC-MS/MS) assay for sepantronium bromide (YM155), an inhibitor of survivin, was developed and validated. Under reduced light exposure, plasma samples were pre-treated using protein precipitation with acetonitrile containing AT7519 as internal standard. After dilution with water, the extract was directly injected into the reversed-phase liquid chromatographic system. The eluate was transferred into the electrospray interface with positive ionization and compounds detected in the selected reaction monitoring mode of a triple quadrupole mass spectrometer. The assay was validated in a 0.5-100 ng/ml calibration range with r(2) = 0.9981 +/- 0.0007 using double logarithmic calibration (n = 5). Within day precisions (n = 6) were 3.6-8.8% and between day (3 days; n = 18) precisions 6.5-11.1%. Accuracies were between 92 and 111% for the whole calibration range. The light sensitive drug sepantronium was sufficiently stable under all relevant analytical conditions. Finally, the assay was successfully used to determine plasma drug levels in mice after administration of sepantronium bromide by continuous infusion from subcutaneously implanted osmotic pumps. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:144 / 148
页数:5
相关论文
共 50 条
  • [1] Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155
    Mitsuoka, Keisuke
    Kita, Aya
    Murakami, Yoshihiro
    Shirasuna, Kenna
    Noda, Akihiro
    Yamanaka, Kentaro
    Kaneko, Naoki
    Miyoshi, Sosuke
    NUCLEAR MEDICINE AND BIOLOGY, 2018, 64-65 : 41 - 46
  • [2] Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma
    Minematsu, Tsuyoshi
    Felder, Laurie
    Oppeneer, Todd
    Sakazume, Masashi
    Oikawa, Keishi
    Hashimoto, Tadashi
    Usui, Takashi
    Kamimura, Hidetaka
    BIOMEDICAL CHROMATOGRAPHY, 2008, 22 (07) : 763 - 769
  • [3] Predicting response to Sepantronium bromide (YM155), a selective survivin suppressant, by PET imaging with 11C-YM155
    Mitsuoka, K.
    Miyoshi, S.
    Murakami, Y.
    Noda, A.
    Kita, A.
    Yamanaka, K.
    Nakahara, T.
    Nishimura, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S259 - S259
  • [4] Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant
    Kawano, Hiroki
    Shakushiro, Kohsuke
    Nakata, Mari
    Kita, Aya
    Maeda, Atsushi
    Watanabe, Shunsuke
    Sako, Kazuhiro
    Oku, Naoto
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 88 (01) : 283 - 289
  • [5] Formulation Design and Evaluation of Liposomal Sepantronium Bromide (YM155), a Small-Molecule Survivin Suppressant, Based on Pharmacokinetic Modeling and Simulation
    Kohsuke Shakushiro
    Hiroki Kawano
    Mari Nakata
    Aya Kita
    Atsushi Maeda
    Shunsuke Watanabe
    Kazuhiro Sako
    Naoto Oku
    Pharmaceutical Research, 2015, 32 : 238 - 247
  • [6] Formulation Design and Evaluation of Liposomal Sepantronium Bromide (YM155), a Small-Molecule Survivin Suppressant, Based on Pharmacokinetic Modeling and Simulation
    Shakushiro, Kohsuke
    Kawano, Hiroki
    Nakata, Mari
    Kita, Aya
    Maeda, Atsushi
    Watanabe, Shunsuke
    Sako, Kazuhiro
    Oku, Naoto
    PHARMACEUTICAL RESEARCH, 2015, 32 (01) : 238 - 247
  • [7] Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma
    Sparidans, Rolf W.
    Tang, Seng Chuan
    Nguyen, Luan N.
    Schinkel, Alfred H.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 905 : 150 - 154
  • [8] Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma
    Sparidans, Rolf W.
    Iusuf, Dilek
    Schinkel, Alfred H.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (32): : 4090 - 4096
  • [9] Liquid chromatography-tandem mass spectrometric assay for the light sensitive calcium channel antagonist lacidipine in human plasma
    Karra, Vijaya Kumari
    Pilli, Nageswara Rao
    Polagani, Srinivasa Rao
    Inamadugu, Jaswanth Kumar
    Rao, J. V. L. N. Seshagiri
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2012, 66 : 211 - 217
  • [10] Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma
    Sparidans, Rolf W.
    Durmus, Selvi
    Schinkel, Alfred H.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2013, 925 : 124 - 128